



August 8, 2025

Press Release

Company name: SEED Co., Ltd.

Representative:

Takao Sato, President, & CEO, Representative Director
(Stock Code: 7743; Tokyo Stock Exchange Prime Market)

Inquiries:

Tetsuya Sugiyama, Executive Vice President, Representative
Director and General Manager of Administration Division
TEL 03-3813-1111 (main)

Notice Concerning Acquisition of Fixed Assets (Kounosu laboratory Building No.4 Phase II Plan)

SEED Co., Ltd. (the "Company") announces the at the Board of Directors meeting held on August 8, 2025, it resolved to acquire the fixed assets listed below for the purpose of increasing production capacity.

1. Reasons for acquiring fixed assets

In the medium-term management plan (April 2024 to March 2027) that started in April 2024, the Company has been working to establish a mass production system for products, including new products, as a pillar of its growth strategy in order to demonstrate its presence in the contact lens market, which is expected to expand in Japan and overseas due to the increasing number of nearsighted people.

At the Kounosu Laboratory, our production base, the Phase 1 Plan for Building No.4 is progressing smoothly with the start of production in March 2026. However, we have decided to launch the Phase 2 Plan for Building No.4 in order to realize growth that will surely capture market expansion by further expanding production capacity and at the same time introduce new materials. In the second phase of the No. 4 Building plan, we will carry out interior work on the third floor, which was designated as room for expansion in the first phase plan, and introduce manufacturing facilities. As the production capacity will be improved, the Company will establish a stable supply system for products. Therefore, the Company plans to launch a new product production line for the launch of next-generation silicone hydrogel lens products by remodeling existing facilities.

With the completion of the second phase of the No.4 building project, the production capacity of the Kounosu laboratory is expected to increase to 89.5 million wafers, more than 150% of the capacity at the beginning of the medium-term management plan.

2. Details of the Assets to be Acquired

(1) Location	1030-7 Fukuro Kounosu-shi Saitama-ken Japan
(2) Use	Equipment on the 3rd floor of Building No,4 and contact lens manufacturing equipment
(3) Total planned investment amount	11.59 billion yen (planned)
(4) Financial plan	Partial lease, borrowing from financial institutions and own funds (details to be determined)

(5) Construction period	Construction scheduled to begin in July 2026 / Operation scheduled to begin in April 2027
(6) Manufacturing capacity after completion, etc.	It will be possible to manufacture contact lenses that are disposable for one day and made of new materials. At present, we are planning to increase production capacity by 10.5 million wafers per month as part of the second phase of the plan.
(7) Others	(Reference) Building No.1: Building area: 7,658.62 m ² / Total floor area: 14,180.39 m ² Building No.2: Building area: 4,906.74 m ² / Total floor area: 9,520.71 m ² Annex of Building No.2: Building area: 1,393.31 m ² / Total floor area: 1,393.31 m ² Building No.3: Building area: 6,714.46 m ² / Total floor area: 12,834.36 m ² Building No.4: Building area: 5,429.61 m ² / Total floor area: 16,399.92 m ²

3. Future prospects

The second phase of operation of Building No.4 will begin in the fiscal year ending March 2028, so the impact of this matter on the financial results for this fiscal year will be minor. If we determine that any events that may affect our financial results arise due to future progress, we will promptly disclose such information.

Kounosu laboratory Building No.4 completed Perth

